Cirrhosis, Liver Clinical Trial
Official title:
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES)
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
This is a multi-national, multicenter, double-blind, randomized, placebo-controlled study in participants with well-compensated NASH cirrhosis. Participants will be randomized 3:1 in a blinded manner to receive 80 mg resmetirom or matching placebo given orally once daily in the morning for the duration of the study (until the required number of Composite Clinical Outcome events are achieved). Composite Clinical Outcome events are defined as any of the following: liver-related and CV mortality, liver transplant, and significant hepatic events, including potential hepatic decompensation events (ascites, hepatic encephalopathy, or gastroesophageal variceal hemorrhage), and confirmed increase of Model for End-stage Liver Disease (MELD) score from <12 to ≥15. The study comprises an up to 60-day screening period and an approximately 3-year treatment period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05793983 -
S100A8/A9 and Innate Immunity in Liver Disease
|
||
| Completed |
NCT04604860 -
Use of EL-FIT App to Promote Physical Activity
|
N/A | |
| Recruiting |
NCT05928624 -
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
|
N/A | |
| Active, not recruiting |
NCT01438970 -
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
|
Phase 2 | |
| Recruiting |
NCT05998330 -
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
|
N/A | |
| Completed |
NCT04581369 -
Cirrhosis Medical Home
|
N/A | |
| Withdrawn |
NCT04244877 -
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
|
Phase 3 | |
| Recruiting |
NCT04588077 -
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
|
Phase 4 | |
| Recruiting |
NCT05538962 -
Longitudinal Monitoring of Inflammation in Cirrhosis
|
N/A | |
| Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
| Completed |
NCT03850977 -
Is There an Association Between Chronic Pancreatitis and Pulmonary Function
|
||
| Active, not recruiting |
NCT03736265 -
Carvedilol for Prevention of Esophageal Varices Progression
|
N/A | |
| Recruiting |
NCT04530760 -
Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
|
||
| Recruiting |
NCT05093218 -
Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease.
|
N/A | |
| Recruiting |
NCT03437876 -
Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis
|
N/A | |
| Recruiting |
NCT05604274 -
Longitudinal Monitoring of Stool Characteristics
|
||
| Recruiting |
NCT04867954 -
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
|
||
| Completed |
NCT04643795 -
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
| Completed |
NCT04121520 -
Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
|